Inbakicept

DB16479

biotech investigational

Deskripsi

Inbakicept is a dimeric human IL-15 receptor ? (IL-15R?) sushi domain/human IgG1 Fc fusion protein. It is one of the active ingredients in Anktiva, a combination product also containing nogapendekin alfa, where a single inbakicept is complexed with two nogapendekin alfa components.^L50592 This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours.^L50627 Non-muscle invasive bladder cancer (NMIBC), which accounts for 75% of all bladder tumours, is commonly treated with transurethral resection of the bladder tumour and Bacillus Calmette-Guérin (BCG) immunotherapy; however, NMIBC is associated with a risk of disease recurrence or progression into advanced disease despite initial treatment with BCG.A263617, A263622 Inbakicept, in combination with nogapendekin alfa, mimics the actions of IL-15, stimulating the activation and proliferation of natural killer cells and CD8+ memory T cells, which also synergistically enhance BCG efficacy.A263617, A263622

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler

Obat Target Gen Interaksi Enzim Transporter Carrier

Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

1. Pendahuluan & Konsep

Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).

2. Sumber Data (Validasi)

Data Obat: Diekstraksi dari elemen drugbank-id dan name pada skema XML DrugBank.
Target Protein: Diambil dari elemen targets/target yang memuat polipeptida sasaran.
Genetik: Disinkronisasi dari sub-elemen gene-name dan varian snp-effects.
Genetik: Jumlah titik node dibatasi pada maksimal 10 (Slice=10) interaksi untuk menghindari tumpukan data.

3. Algoritma Visualisasi

Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.

4. Legenda Visual

Obat Utama (Pusat Analisis)

Target Protein (Mekanisme)

Gen (Faktor Genetik)

Metode ini mendukung analisis Precision Medicine dan evaluasi risiko Drug-Drug Interaction (DDI).

Profil Farmakokinetik

Waktu Paruh (Half-Life) -

Volume Distribusi -

Klirens (Clearance) -

Absorpsi

Systemic exposure of nogapendekin alfa-inbakicept complex was less than 100 pg/mL following the approved recommended dosage in all patients. This was below the lower limit of quantitation in all patients.^L50592

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

39 Data

Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Inbakicept.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Inbakicept.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Inbakicept.
Methoxy polyethylene glycol-epoetin beta	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Inbakicept.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Lidocaine.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Ropivacaine.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Bupivacaine.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Cinchocaine.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Dyclonine.
Procaine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Procaine.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Prilocaine.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Proparacaine.
Meloxicam	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Meloxicam.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Oxybuprocaine.
Cocaine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Cocaine.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Mepivacaine.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Levobupivacaine.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Diphenhydramine.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Benzocaine.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Chloroprocaine.
Phenol	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Phenol.
Tetrodotoxin	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Tetrodotoxin.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Benzyl alcohol.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Capsaicin.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Etidocaine.
Articaine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Articaine.
Tetracaine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Tetracaine.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Propoxycaine.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Pramocaine.
Butamben	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Butamben.
Butacaine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Butacaine.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Oxetacaine.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Ethyl chloride.
Butanilicaine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Butanilicaine.
Metabutethamine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Metabutethamine.
Quinisocaine	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Quinisocaine.
Nelarabine	The risk or severity of adverse effects can be increased when Nelarabine is combined with Inbakicept.
Ambroxol	The risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Ambroxol.
Etrasimod	The risk or severity of immunosuppression can be increased when Inbakicept is combined with Etrasimod.

Target Protein

Interleukin-2 receptor subunit beta IL2RB

Cytokine receptor common subunit gamma IL2RG

Referensi & Sumber

Artikel (PubMed)

PMID: 33996264
Rosser CJ, Tikhonenkov S, Nix JW, Chan OTM, Ianculescu I, Reddy S, Soon-Shiong P: Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guerin (BCG) for the Treatment of Bladder Cancer. Oncoimmunology. 2021 May 3;10(1):1912885. doi: 10.1080/2162402X.2021.1912885.
PMID: 37224225
de Jong FC, Laajala TD, Hoedemaeker RF, Jordan KR, van der Made ACJ, Boeve ER, van der Schoot DKE, Nieuwkamer B, Janssen EAM, Mahmoudi T, Boormans JL, Theodorescu D, Costello JC, Zuiverloon TCM: Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Guerin. Sci Transl Med. 2023 May 24;15(697):eabn4118. doi: 10.1126/scitranslmed.abn4118. Epub 2023 May 24.
PMID: 38320011
Chamie K, Chang SS, Kramolowsky E, Gonzalgo ML, Agarwal PK, Bassett JC, Bjurlin M, Cher ML, Clark W, Cowan BE, David R, Goldfischer E, Guru K, Jalkut MW, Kaffenberger SD, Kaminetsky J, Katz AE, Koo AS, Sexton WJ, Tikhonenkov SN, Trabulsi EJ, Trainer AF, Spilman P, Huang M, Bhar P, Taha SA, Sender L, Reddy S, Soon-Shiong P: IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer. NEJM Evid. 2023 Jan;2(1):EVIDoa2200167. doi: 10.1056/EVIDoa2200167. Epub 2022 Nov 10.
PMID: 32163523
Webb GM, Molden J, Busman-Sahay K, Abdulhaqq S, Wu HL, Weber WC, Bateman KB, Reed JS, Northrup M, Maier N, Tanaka S, Gao L, Davey B, Carpenter BL, Axthelm MK, Stanton JJ, Smedley J, Greene JM, Safrit JT, Estes JD, Skinner PJ, Sacha JB: The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques. PLoS Pathog. 2020 Mar 12;16(3):e1008339. doi: 10.1371/journal.ppat.1008339. eCollection 2020 Mar.

Link

Contoh Produk & Brand

Produk: 0 • International brands: 0

Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.